Danshen for Health & Longevity - Quick Reference Sheet

Danshen for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Danshen is a traditional Chinese root herb used for blood circulation, heart and kidney health, and male urinary function. For standalone oral extracts, human evidence reaches a medium level only for relieving male urinary symptoms and supporting erectile function. Heart, kidney, and stroke claims rest on low or conflicted evidence, while oral use can raise harmful cholesterol, speed up prescription medication breakdown, and cause severe bleeding with warfarin. (Full Review)

Protocol

Standardized root extract (urological protocol)
400 or 800 mg/day orally
Oral SAGX extract for 12 weeks for male LUTS and erectile function (400 mg/day in adults over 65 or with fasting LDL > 3.5 mmol/L)
Hydrophilic aqueous extract (cardiometabolic protocol)
1,000 mg 2–3× daily (2–3 g/day)
Oral aqueous extract in outpatient antioxidant and blood pressure trials (or 10–15 g/day dried root decoction; 270 mg CDDP 3× daily)
Optimal time of day
Split into 2–3 doses with meals
Administered with morning and evening meals (plus midday for thrice-daily regimens) to match 1–6 hour half-lives, reduce gastric irritation, and enhance absorption
Time to effect
Lower Urinary Tract Symptoms and Erectile Function
8 to 12 weeks
IPSS urinary symptom relief and IIEF erectile function improvement (assessed at 4 and 12 weeks)
Systemic Antioxidant Enzyme Upregulation
30 to 60 days
MDA declines by 30 days and SOD rises by 60 days in diabetic CHD
CYP3A4 and P-gp Enzyme Induction
7 to 14 days
Emerges in 7 to 14 days of oral use (resolves within 1 to 2 weeks after cessation)

Benefits

Contraindications
  • Patients taking anticoagulants or clopidogrel (warfarin, acenocoumarol, rivaroxaban, apixaban, dabigatran, clopidogrel, prasugrel)
  • Patients with bleeding disorders or prior cerebral hemorrhage (hemorrhagic diathesis, thrombocytopenia, active peptic ulceration)
  • Patients with acute unstable cardiovascular conditions (acute coronary syndrome within 2 months, coronary revascularization within 6 months, decompensated heart failure, seated systolic blood pressure > 180 mmHg or diastolic > 110 mmHg)
  • Perioperative and surgical patients (elective surgery, dental extraction, or invasive procedures within 14 days)
  • Pregnant or lactating women
Key Interactions
  • CYP3A4 substrates (midazolam, amlodipine, cyclosporine, tacrolimus)
  • P-gp substrates (fexofenadine, digoxin)
  • BCRP and organic anion transporting polypeptide (OATP) substrates (rosuvastatin, atorvastatin)
  • Over-the-counter salicylates and nonsteroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen, naproxen)
  • Antiplatelet and hypotensive supplements (garlic, Ginkgo biloba, Panax ginseng, nattokinase, omega-3 fatty acids; theoretical)
  • Clinical laboratory digoxin immunoassays (fluorescence polarization and microparticle enzyme assays)

Risk & Side Effects

  • High: Subtherapeutic exposure of co-administered medications
  • Medium:
  • Low: Low-density lipoprotein cholesterol elevation; warfarin potentiation and severe hemorrhage; mild gastrointestinal discomfort and vasodilatory headache; serum digoxin immunoassay interference; cutaneous hypersensitivity and borneol-related methemoglobinemia
  • Speculative: Embryo-fetal resorption and uteroplacental perfusion alteration; supratherapeutic hepatic cytochrome hypertrophy

Monitoring

Marker Target Why
Fasting LDL Cholesterol < 2.6 mmol/L (< 100 mg/dL; cessation threshold: rise ≥ 0.30 mmol/L) Safety check and conflicted efficacy marker: oral aqueous Danshen raised LDL by 0.30 mmol/L in hyperlipidemic adults
Seated or 24-Hour Ambulatory Blood Pressure < 130/80 mmHg (standard < 120/80 mmHg) Expected efficacy marker: tracks vascular response in mild-to-moderate hypertension
eGFR and Serum Creatinine ≥ 90 mL/min/1.73 m² (paired with spot urine albumin-to-creatinine ratio) Expected efficacy and safety marker: tracks renal filtration preservation in kidney disease
Platelet Count (via CBC) and PT/INR Platelets 150–450 × 10⁹/L; INR 0.8–1.2 Safety check: detects rare reversible thrombocytopenia or coagulopathy (cessation threshold: platelets < 150 × 10⁹/L)
IPSS and IIEF Questionnaires Reduction in IPSS and increase in IIEF from individual baseline (no established target) Expected efficacy marker: quantifies LUTS relief and erectile function in men

Cadence: Baseline testing before initiation; re-evaluate blood pressure and qualitative tolerance at 2 to 4 weeks (and IPSS/IIEF at 4 weeks); repeat fasting LDL cholesterol, CBC, and renal panels at 4 to 8 weeks; assess full clinical efficacy at 12 weeks; repeat labs every 6 months during cyclical use.

Qualitative Assessment

  • Urinary symptoms: Nocturia frequency and bladder emptying
  • Chest comfort: Exertional chest tightness and nitroglycerin use
  • Bleeding and digestion: Bruising, epistaxis (nosebleeds), or postprandial dyspepsia